Question explored with the scientific record
shingles vaccine for 57 year old who had chicken pox at 20 years old
For a 57-year-old with prior chickenpox, the recombinant zoster vaccine (Shingrix) shows strong evidence of benefit, but the safety data is thin on long-term harms and relies on manufacturer-funded trials.
The evidence comes almost entirely from GSK-funded trials [1, 5, 6]. In the pivotal ZOE-50 trial, two doses cut herpes zoster incidence by 97.2% over 3.5 years in adults 50+ [2, 5]. A real-world Medicare study found lower effectiveness of about 70% after two doses [3], which is still substantial. Protection lasts at least 8-10 years [3, 4]. Your prior chickenpox means you carry the latent virus, so the vaccine's job is to boost your immune memory against it.
The safety picture is more limited. The vaccine causes frequent local reactions: about 79% reported injection-site pain versus 11% on placebo [5]. Serious adverse events over 3-4 years were similar to placebo (about 9% in both groups) [5]. A small signal for Guillain-Barré syndrome was detected at about 3 extra cases per million doses [3]. No long-term safety study beyond 10 years exists, and the trials compared vaccinated people to placebo, not to an unvaccinated group followed for decades.
| Group | HZ incidence per 1000 person-years | Vaccine efficacy |
|---|---|---|
| ZOE-50 (50+, trial) | 0.3 vs 9.1 placebo | 97.2% |
| ZOE-70 (70+, trial) | 0.9 vs 9.2 placebo | 89.8% |
| Medicare (65+, real-world) | Not directly reported | ~70% after 2 doses |
The key gap: no trial has compared vaccinated to unvaccinated people over 10+ years for rare harms. The vaccine is likely net beneficial for a 57-year-old, but the evidence base is narrower than advertised.
My call: the vaccine reduces shingles risk substantially for about a decade, with common but temporary side effects. Confidence: moderate.
Sources used 6
-
Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients
A phase IIIB, non-randomized, open-label study assessing the safety of the adjuvanted recombinant zoster vaccine (RZV) in adults aged 50+ who previously received placebo in ZOE-50/ZOE-70, finding a safety profile consistent with prior trials, with most adverse events being mild-…
DOI: 10.1016/j.vaccine.2020.10.029 -
Evaluating the Immunogenicity, Efficacy, and Effectiveness of Recombinant Zoster Vaccine for Global Public Health Policy
RZV is highly effective against herpes zoster and its complications, with protection lasting at least 10 years across age groups and in immunocompromised populations, but policy decisions require additional considerations such as cost-effectiveness and disease burden data.
DOI: 10.3390/vaccines13030250 -
Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
This narrative review finds real-world vaccine effectiveness of about 46% for live zoster vaccine and about 85% for recombinant zoster vaccine, with mostly local reactions and a small Guillain-Barré syndrome signal to monitor.
DOI: 10.3390/v14122667 -
What is Different about Recombinant Herpes Zoster Vaccine?
This narrative review concludes that recombinant zoster vaccine is more effective and longer-lasting than live zoster vaccine, has an acceptable safety profile, and is recommended for adults aged ≥50 years and severely immunocompromised adults aged ≥18 years.
DOI: 10.3904/kjm.2024.99.4.180 -
Zoster Vaccine Recombinant, Adjuvanted
In a narrative review of clinical trial data, adjuvanted recombinant zoster vaccine (Shingrix) showed high efficacy against herpes zoster and postherpetic neuralgia in adults 50 years and older, with mainly transient local and systemic reactions.
DOI: 10.1177/0018578718767103 -
Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials
In a pooled post hoc analysis of the ZOE-50/70 trials, the adjuvanted recombinant zoster vaccine was 90.5% efficacious against herpes zoster in adults with pre-existing potential immune-mediated diseases, with SAE and fatal SAE rates similar to placebo.
DOI: 10.1093/rheumatology/keaa424